Argenx to Buy Forte Biosciences for $2.2 Billion

2026-07-27 | original

read original more articles

The deal to acquire the Nasdaq-listed Forte represents a 41% premium to its closing price on Friday.

Explore topics: argenx forte biosciences nasdaq acquisition biotech